Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−118 JPY
−756.45 M JPY
80.04 M JPY
5.22 M
About KRINGLE PHARMA INC
Sector
Industry
CEO
Kiichi Adachi
Website
Headquarters
Osaka
Founded
2001
ISIN
JP3270790003
FIGI
BBG00YB3CTD5
Kringle Pharma, Inc. engages in the research and development of treatments for regenerative medicine and cancer therapy. It specializes in the research of hepatocyte growth factor (HGF), an intrinsic factor with an organotrophic role in the regeneration and repair of tissues and organs. It also provides research and development of NK4, a multi-targeted angiogenesis inhibitor and a cancer therapeutic. The company was founded by Kunio Matsumoto and Toshikazu Nakamura on December 21, 2001 and is headquartered in Osaka, Japan.
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
The current price of 4884 is 835 JPY — it has increased by 4.11% in the past 24 hours. Watch KRINGLE PHARMA INC stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on TSE exchange KRINGLE PHARMA INC stocks are traded under the ticker 4884.
4884 stock has risen by 2.83% compared to the previous week, the month change is a −7.73% fall, over the last year KRINGLE PHARMA INC has showed a 15.49% increase.
4884 reached its all-time high on Dec 28, 2020 with the price of 1,780 JPY, and its all-time low was 394 JPY and was reached on Feb 16, 2024. View more price dynamics on 4884 chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
4884 stock is 5.89% volatile and has beta coefficient of 1.55. Track KRINGLE PHARMA INC stock price on the chart and check out the list of the most volatile stocks — is KRINGLE PHARMA INC there?
Yes, you can track KRINGLE PHARMA INC financials in yearly and quarterly reports right on TradingView.
KRINGLE PHARMA INC is going to release the next earnings report on Feb 7, 2025. Keep track of upcoming events with our Earnings Calendar.
4884 net income for the last quarter is −238.03 M JPY, while the quarter before that showed −152.20 M JPY of net income which accounts for −56.39% change. Track more KRINGLE PHARMA INC financial stats to get the full picture.
No, 4884 doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Dec 27, 2024, the company has 15.00 employees. See our rating of the largest employees — is KRINGLE PHARMA INC on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. KRINGLE PHARMA INC EBITDA is −817.88 M JPY, and current EBITDA margin is −1.02 K%. See more stats in KRINGLE PHARMA INC financial statements.
Like other stocks, 4884 shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade KRINGLE PHARMA INC stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So KRINGLE PHARMA INC technincal analysis shows the neutral today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating KRINGLE PHARMA INC stock shows the buy signal. See more of KRINGLE PHARMA INC technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.